Jacobs Levy Equity Management Inc. Has $162.48 Million Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Jacobs Levy Equity Management Inc. grew its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 17.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,731,313 shares of the company’s stock after buying an additional 259,316 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in GE HealthCare Technologies were worth $162,484,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of GEHC. Atria Investments Inc acquired a new stake in GE HealthCare Technologies during the 1st quarter valued at $1,300,000. Cetera Investment Advisers boosted its stake in GE HealthCare Technologies by 569.9% in the 1st quarter. Cetera Investment Advisers now owns 68,474 shares of the company’s stock valued at $6,225,000 after purchasing an additional 58,252 shares during the period. Cetera Advisors LLC grew its holdings in GE HealthCare Technologies by 71.7% in the 1st quarter. Cetera Advisors LLC now owns 26,132 shares of the company’s stock valued at $2,376,000 after buying an additional 10,908 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of GE HealthCare Technologies by 191.4% during the first quarter. EverSource Wealth Advisors LLC now owns 1,463 shares of the company’s stock worth $133,000 after buying an additional 961 shares in the last quarter. Finally, DNB Asset Management AS boosted its holdings in GE HealthCare Technologies by 13.9% in the 2nd quarter. DNB Asset Management AS now owns 68,531 shares of the company’s stock valued at $5,340,000 after purchasing an additional 8,343 shares during the period. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock opened at $83.08 on Tuesday. GE HealthCare Technologies Inc. has a 1-year low of $67.00 and a 1-year high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. The business has a 50-day moving average price of $87.78 and a two-hundred day moving average price of $83.65. The company has a market cap of $37.96 billion, a P/E ratio of 22.82, a PEG ratio of 2.98 and a beta of 1.08.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $0.99 EPS. As a group, analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be issued a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. The ex-dividend date is Tuesday, January 14th. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.30%.

Analyst Ratings Changes

GEHC has been the subject of several analyst reports. BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Wednesday, September 18th. Wells Fargo & Company upped their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Evercore ISI lifted their price target on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus lifted their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Finally, UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $84.00 to $74.00 in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.46.

Insider Buying and Selling

In related news, CEO Roland Rott sold 3,577 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by corporate insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.